In December 2017, the FDA approved a DNA altering medication that can reverse an inherited form of progressive blindness. Luxturna is a gene therapy which can treat a condition called Leber's Congenital Amaurosis (LCA) wherein people have inherited two faulty copies of the RPE65 gene. The therapy replaces those faulty genes with normal versions, thus erasing the mutations' harmful effects. A single injection in each eye has shown to be enough to improve lost vision. We are talking to the doctor couple, Dr. Jean Bennett of University of Pennsylvania and Dr. Albert M. Maguire of Childrens' Hospital of Philadelhia (CHOP), whose work for more than 25 years on congenital blindness led to this ground breaking FDA approval. Join us to learn about the novel therapy, details on treatment procedure and recovery.
#blindness #RPE65 #LCA #LCAkids
This talk has been created by CureTalks.com, in association with University of Pennsylvania to facilitate discussions for solutions, with a mission to heal the world through information and sharing of knowledge. At CureTalks we discuss groundbreaking medical research including a wide range of medical, health, and wellness issues, bringing together the doctors, researchers and patients on the same platform.
SUBSCRIBE!
kzitem.info?s...
LET'S CONNECT!
Website: https: www.curetalks.com/
Facebook: / curetalks
Instagram: / cure_talks_tx
Linkedin: www.linkedin.com/company/cure...
Twitter : / curetalks
Pinterest: / _saved
Негізгі бет Reversing Blindness with New FDA Approved Retinal Gene Therapy
Пікірлер: 11